MRI and 18FDG-PET in the assessment of bone marrow infiltration of the spine in cancer patients

[1]  J. Richter,et al.  Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  H. Lundqvist,et al.  Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Jonathan Goldin,et al.  Accuracy of PET/CT in characterization of solitary pulmonary lesions. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  Badreddine Bencherif,et al.  18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  E. Hindié,et al.  18F-FDG PET/CT visualisation of tumor seeding after percutaneous radiofrequency ablation of metastases , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  M. Ranson,et al.  Does 124Iodo-deoxyuridine measure cell proliferation in NSCLC? Initial investigations with PET imaging and radio-metabolite analysis , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  W. Oyen,et al.  Comparison of Multiphase CT, FDG-PET and Intra-Operative Ultrasound in Patients with Colorectal Liver Metastases Selected for Surgery , 2007, Annals of Surgical Oncology.

[8]  W. Oyen,et al.  The Role of FDG-PET in the Selection of Patients with Colorectal Liver Metastases , 2007, Annals of Surgical Oncology.

[9]  L. Brepoels,et al.  PET and PET/CT for response evaluation in lymphoma: Current practice and developments , 2007, Leukemia & lymphoma.

[10]  P. Julyan,et al.  Should FDG-PET scanning be routinely used for patients with an unknown head and neck squamous primary? , 2006, The Journal of Laryngology & Otology.

[11]  A. Luini,et al.  Role of fluorodeoxyglucose positron emission tomography in the staging of patients with breast cancer candidated to surgery. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E. Stoelben,et al.  Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  L. Fayad,et al.  Sacral fractures: a potential pitfall of FDG positron emission tomography. , 2003, AJR. American journal of roentgenology.

[14]  A. Ellis.  Breast , 2002, BMJ : British Medical Journal.

[15]  M. Reiser,et al.  Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? , 2002, Cancer.

[16]  M. Langer,et al.  Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumors of the axial skeleton. , 2002, European journal of radiology.

[17]  W. Heindel,et al.  FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  E. Moser,et al.  Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. , 2001, European journal of radiology.

[19]  O. Schober,et al.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.

[20]  O. Schober,et al.  FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy , 2000, European Journal of Nuclear Medicine.

[21]  C. Kao,et al.  Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. , 2000, Anticancer research.

[22]  S. Reske,et al.  FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  H. Schirrmeister,et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Bares.  Skeletal scintigraphy in breast cancer management. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[26]  M. Langer,et al.  Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Wahl,et al.  Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.

[28]  V. Diehl,et al.  Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. , 1995, Journal of Clinical Oncology.

[29]  J. Hainsworth,et al.  Breast cancer with skeletal metastases at initial diagnosis: Distinctive clinical characteristics and favorable prognosis , 1986, Cancer.

[30]  E. Silberstein,et al.  Bone scintigraphy screening in stage I-II breast cancer: is it cost-effective? , 1996, Cleveland Clinic journal of medicine.

[31]  Hakon Hakonarson,et al.  THE CHILDREN'S HOSPITAL OF PHILADELPHIA. , 1955, British medical journal.

[32]  Norman Goldstein,et al.  Metastases in carcinoma. Analysis of 1000 autopsied cases , 1950, Cancer.

[33]  O. M. Friedman,et al.  Distribution of radioactivity in rats and man. After intravenous administration of diethyl β‐radioiodoethyl amine hydrochloride and of radioactive sodium iodide , 1950 .